Acrivon Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Acrivon Therapeutics Common
ACRV Stock   2.46  0.05  2.07%   
Acrivon Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Acrivon Therapeutics' valuation are provided below:
Market Capitalization
77.6 M
Earnings Share
(2.12)
There are over one hundred nineteen available fundamental signals for Acrivon Therapeutics Common, which can be analyzed over time and compared to other ratios. All traders should should validate Acrivon Therapeutics' prevailing fundamental trends against the trends from 2010 to 2026 to make sure the company is sustainable. Market Cap is likely to climb to about 1.9 B in 2026. Enterprise Value is likely to climb to about 1.9 B in 2026
Check Acrivon Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Acrivon Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.2 M, Selling General Administrative of 30.4 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 10.87. Acrivon financial statements analysis is a perfect complement when working with Acrivon Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Acrivon Stock
Check out the analysis of Acrivon Therapeutics Correlation against competitors.

Acrivon Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets137.5 M226.1 M59.4 M
Slightly volatile
Short and Long Term Debt Total4.2 M4.2 M1.6 M
Slightly volatile
Other Current Liabilities18.6 M17.7 M4.1 M
Slightly volatile
Total Current Liabilities20.8 M19.8 M5.1 M
Slightly volatile
Property Plant And Equipment Net6.3 M9.2 M2.6 M
Slightly volatile
Accounts Payable1.7 M871.7 K691.8 K
Slightly volatile
Cash45.4 M45.8 M18.4 M
Slightly volatile
Non Current Assets Total17.4 M17.2 M7 M
Slightly volatile
Non Currrent Assets Other2.2 M2.1 M712.5 K
Slightly volatile
Other Assets0.860.9309 K
Slightly volatile
Cash And Short Term Investments117.9 M206.4 M51.5 M
Slightly volatile
Common Stock Shares Outstanding23.8 M44 M17.9 M
Slightly volatile
Liabilities And Stockholders Equity137.5 M226.1 M59.4 M
Slightly volatile
Non Current Liabilities Total2.2 M2.3 M14.8 M
Very volatile
Other Current Assets2.1 M2.5 M919.2 K
Slightly volatile
Other Stockholder Equity450.7 M429.3 M101.2 M
Slightly volatile
Total Liabilities30.2 M17.8 M20.2 M
Slightly volatile
Property Plant And Equipment Gross7.1 M11.5 M3 M
Slightly volatile
Short and Long Term Debt46.4 K52.2 K57 K
Slightly volatile
Total Current Assets120 M208.9 M52.4 M
Slightly volatile
Capital Stock37.4 K35.6 K9.5 K
Slightly volatile
Net Working Capital111.1 M189.1 M48 M
Slightly volatile
Short Term Debt744 K1.2 M348.3 K
Slightly volatile
Common Stock37.4 K35.6 K9.5 K
Slightly volatile
Property Plant Equipment2.9 M2.4 M1.1 M
Slightly volatile
Current Deferred Revenue74.2 K79.3 K67.8 K
Slightly volatile
Common Stock Total Equity17.6 K19.8 K21.6 K
Slightly volatile
Capital Surpluse181.3 M203.9 M222.6 M
Slightly volatile
Non Current Liabilities Other3.4 M3.8 M4.2 M
Slightly volatile

Acrivon Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.2 M1.2 M262.2 K
Slightly volatile
Selling General Administrative30.4 M29 M7.7 M
Slightly volatile
Other Operating Expenses107.7 M102.6 M26.5 M
Slightly volatile
Research Development77.3 M73.6 M18.7 M
Slightly volatile
Cost Of Revenue766 K1.2 M325.6 K
Slightly volatile
Total Operating Expenses106.5 M101.4 M26.3 M
Slightly volatile
Reconciled Depreciation1.2 M1.2 M260.8 K
Slightly volatile
Interest Expense1.8 M1.7 M511.2 K
Slightly volatile
Non Operating Income Net Other1.2 M1.3 M1.5 M
Slightly volatile
Net Interest Income8.9 M10.6 M7.5 M
Slightly volatile
Interest Income8.9 M10.6 M7.5 M
Slightly volatile
Selling And Marketing Expenses107.2 K120.6 K131.6 K
Slightly volatile

Acrivon Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation17.3 M16.4 M3.7 M
Slightly volatile
Begin Period Cash Flow37.5 M41.9 M15.8 M
Slightly volatile
Depreciation1.2 M1.2 M262.2 K
Slightly volatile
Capital Expenditures3.3 M3.2 M773.6 K
Slightly volatile
End Period Cash Flow45.8 M46 M18.8 M
Slightly volatile
Change To Netincome2.3 M2.5 M2.2 M
Slightly volatile
Sale Purchase Of Stock81.4 M91.5 M99.9 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation4.113.162.2059
Slightly volatile
Payables Turnover1.251.190.4117
Slightly volatile
Cash Per Share0.450.481.0983
Slightly volatile
Days Payables Outstanding3003162.8 K
Slightly volatile
Income Quality0.620.730.6182
Slightly volatile
Current Ratio17.1312.137.9492
Slightly volatile
Capex Per Share0.0070.00740.0117
Slightly volatile
Interest Debt Per Share0.01180.01240.3551
Slightly volatile
Debt To Assets0.02030.02132.9843
Slightly volatile
Days Of Payables Outstanding3003162.8 K
Slightly volatile
Ebt Per Ebit1.191.041.4341
Slightly volatile
Long Term Debt To Capitalization5.085.726.2398
Slightly volatile
Quick Ratio17.1312.137.9492
Slightly volatile
Cash Ratio2.532.664.5487
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio0.820.940.9988
Slightly volatile
Debt Ratio0.02030.02132.9843
Slightly volatile

Acrivon Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.9 B1.8 B606.7 M
Slightly volatile
Enterprise Value1.9 B1.8 B597.3 M
Slightly volatile

Acrivon Fundamental Market Drivers

Acrivon Upcoming Events

26th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
26th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Acrivon Therapeutics Financial Statements

Acrivon Therapeutics investors use historical fundamental indicators, such as Acrivon Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Acrivon Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue79.3 K74.2 K
Cost Of Revenue1.2 M766 K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Acrivon Stock Analysis

When running Acrivon Therapeutics' price analysis, check to measure Acrivon Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acrivon Therapeutics is operating at the current time. Most of Acrivon Therapeutics' value examination focuses on studying past and present price action to predict the probability of Acrivon Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acrivon Therapeutics' price. Additionally, you may evaluate how the addition of Acrivon Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY